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Abstract
Angiogenesis, the formation of new blood vessels, is an essential process for tumour progression and is an area of
significant therapeutic interest. Different in vitro systems and more complex in vivo systems have been described for the
study of tumour angiogenesis. However, there are few human 3D in vitro systems described to date which mimic the
cellular heterogeneity and complexity of angiogenesis within the tumour microenvironment. In this study we describe the
Minitumour model – a 3 dimensional human spheroid-based system consisting of endothelial cells and fibroblasts in co-
culture with the breast cancer cell line MDA-MB-231, for the study of tumour angiogenesis in vitro. After implantation in
collagen-I gels, Minitumour spheroids form quantifiable endothelial capillary-like structures. The endothelial cell pre-
capillary sprouts are supported by the fibroblasts, which act as mural cells, and their growth is increased by the presence of
cancer cells. Characterisation of the Minitumour model using small molecule inhibitors and inhibitory antibodies show that
endothelial sprout formation is dependent on growth factors and cytokines known to be important for tumour
angiogenesis. The model also shows a response to anti-angiogenic agents similar to previously described in vivo data. We
demonstrate that independent manipulation of the different cell types is possible, using common molecular techniques,
before incorporation into the model. This aspect of Minitumour spheroid analysis makes this model ideal for high content
studies of gene function in individual cell types, allowing for the dissection of their roles in cell-cell interactions. Finally,
using this technique, we were able to show the requirement of the metalloproteinase MT1-MMP in endothelial cells and
fibroblasts, but not cancer cells, for sprouting angiogenesis.
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Introduction
Solid tumours are heterogeneous and complex organ-like
structures in which the transformed cancer cell co-exists with
several other cell types. This microenvironment supports the
growth, proliferation, invasion and metastasis of cancer cells
through a complex network of signals propagated by interactions
that include the extracellular matrix (ECM), other cells, growth
factors, chemokines, cytokines and the proteinase system [1,2].
Genetically aberrant cancer cells have been extensively shown to
need this permissive framework in order to proliferate and achieve
their metastatic potential [3,4].
The observation that tumour growth is often accompanied by
neovascularisation has been established since the 70 s, notably
through Judah Folkman’s pioneering work [5]. Since then it has
been well documented that tumours cannot progress without
oxygen and nutrient supply through newly formed vasculature,
which is also essential for the metastatic process [6,7,8]. Without
this process of neovascularisation tumours remain in their
dormant, non-angiogenic form of around 1–2 mm, where
proliferation is balanced with apoptosis, maintaining these
microtumours quiescent [6]. Strategies for targeting angiogenesis
have received significant attention with some degree of clinical
success [9,10]. Tumour angiogenesis is thought to occur mostly via
sprouting angiogenesis. This is a process through which a single
endothelial cell, called the tip cell, is selected from the vasculature,
overcoming its quiescent environment, and forming a new vessel.
The tip cell migrates towards a chemoattractant angiogenic signal
constituted of growth factors that are secreted by the tumour cells
and their stroma, which induces endothelial cell mitogenesis and
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survival [11]. The following endothelial cells acquire a stalk cell
phenotype, stabilizing the vessel through the recruitment of mural
cells and deposition of a basement membrane [12].
A number of methods have been developed recently in which
engineered tumours capture aspects of in vivo processes, allowing
for the study of these processes in a controlled environment.
However few have been successfully applied to the study of tumour
sprouting angiogenesis. The majority of existing models of in vitro
angiogenesis tend to involve the separation of endothelial cells
from cancer cells by a barrier of matrix or membrane, as cancer
cells have been described to induce cell death in endothelial cells
when in direct contact [13]. Several of these models also consist of
variations of the tube formation assay, where endothelial cells are
cultured in different matrix compositions, such as matrigel, fibrin
or collagen, to form cord like structures in vitro [14,15,16]. Whilst
allowing for a more detailed look into endothelial cell differenti-
ation, these models are still somewhat simplistic in their nature, as
they do not account for heterogeneous cell interactions important
for this process. More recently these models have been growing in
complexity. Earlier work has suggested a role for fibroblasts in
inducing tubule formation using 3-dimensional systems where
endothelial cells are separated from fibroblasts by collagen disks
[17]. More complex in vitro models have since been developed
where the fibroblasts are added in direct contact with the
endothelial cells, most notably in a monolayer co-culture of
dermal fibroblasts and human umbilical cord endothelial cells that
allows formation of endothelial cell tubules in vitro [18].
These observations are in accordance to the increasingly
recognised role of fibroblasts, mostly under the form of
carcinoma-associated fibroblasts (CAFs), in cancer development.
While the full complexity of their role is still not fully understood,
the importance of these cells in tumour invasion, progression and
metastasis has been widely documented [19,20]. This role is partly
enacted through the secretion of several growth factors and
cytokines that stimulate tumour growth. CAFs also stimulate
tumour progression through the remodelling of the extracellular
matrix (ECM), notably by the expression of ECM-degrading
proteases, such as Matrix Metalloproteinases (MMPs) [19]. Their
importance for the angiogenic process has also been described,
and is thought to be regulated partly through the secretion of
growth factors including Vascular Endothelial Growth Factor
(VEGF) [4,20].
The importance of the development of 3 dimensional (3D)
models for the study of complex cellular process has been
extensively discussed in the literature. Recent studies have seen
the development of 3D co-culture models for the study of
angiogenesis in vitro, which have suggested the role of mesenchy-
mal cells in vessel formation, as well their requirement to form
endothelial tubules in vitro [21,22,23]. However, to our knowledge,
no such model has yet been developed that allows for the study of
this process in direct cell-cell contact with cancer cells.
The development of 3D in vitro engineered human tumours
which can mimic the complexities of cancer-stromal interactions,
be readily manipulated and quantified and allow for the study of
tumour angiogenesis, bridging the gap between 2D monoculture
and in vivo systems, would be of enormous potential [24,25,26,27].
Previous work by Korff and Augustin has resulted in the
development of a method for culturing endothelial cells as 3-
dimensional spheroids in vitro, which induces endothelial cell
differentiation [28]. Further developments of this technique have
included the introduction of mesenchymal mural components to
support endothelial tubule formation [21,29]. Based on this work,
we have developed the first 3-dimensional in vitro model of tumour
angiogenesis, consisting of a spheroidal co-culture of endothelial
cells, fibroblasts and the tumour cell line MDA-MB-231.
Incubation of these spheroids in type-I collagen leads to the
formation of capillary-like sprouts, which are shown to be a
quantifiable and reproducible model of the early stages of tumour
angiogenesis. This model is further shown to be amenable to
genetic manipulation of individual cell types, which allows for the
identification of new roles for specific genes in cell-cell interactions
leading to endothelial sprout formation, in a cancer environment.
Materials and Methods
Antibodies and reagents
Function blocking antibodies for human VEGF, PDGF-B, IL-6
and IL-8 were purchased from R&D systems (Oxford, UK). The
antibodies used for Western Blotting were as follows: sheep anti-
human MT1-MMP ectodomain polyclonal antibody (clone N175/
6) [30], monoclonal mouse anti-human MT1-MMP catalytic
domain antibody (Clone Lem2/15.8, Millipore, UK), polyclonal
rabbit anti-human antibody to b-actin (Abcam, UK). Secondary
HRP-conjugated antibodies were obtained from Jackson Immu-
noresearch Laboratories (Stratech, UK). Antibodies for immuno-
staining were as follows: monoclonal mouse anti-human tenascin,
polyclonal rabbit anti-human CD34, polyclonal rabbit anti-human
pan-laminin (Abcam, UK), monoclonal mouse anti-human CD31,
monoclonal mouse anti-human collagen-IV (Dako, Ely, UK) and
polyclonal goat anti-human LYVE-1 (R&D Systems, UK).
Secondary donkey anti-mouse and anti-rabbit antibodies conju-
gated with FITC, Texas Red or Cyanine Cy5 fluorophores were
obtained from Jackson ImmunoResearch Laboratories (Stratech,
UK). Endostatin and SU4312 were purchased from Sigma-
Aldrich, UK. Thalidomide, Galardin (GM6001), AG1296 and
PPP were obtained from Merck Biosciences, UK.
Cell culture
Human Umbilical Vein Endothelial Cells (HUVECs) and
Normal Human Dermal Fibroblasts (NHDF) were obtained from
Promocell GmbH (Heidelberg, Germany). The MDA-MB-231
breast cancer cell line was purchased form the European
Collection of Cell Cultures (Dorset, UK). HUVECs were cultured
in Endothelial Cell Growth Medium (ECGM, Promocell),
containing a final concentration of 1 ng/ml basic Fibroblast
Growth Factor, 4 ml/ml Endothelial Growth Supplement/
Heparin, 0.1 ng/ml Epidermal Growth Factor, 1 mg/ml Hydro-
cortisone, 0.62 ng/ml phenol red and 2% (v/v) Fetal Calf Serum.
NHDFs and MDA-MB-231 cells were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM) (Invitrogen, UK) with 10%
FCS (v/v) (Hyclone, Thermo Fisher Scientific, UK), 100 units/ml
Penicilin (Invitrogen), 100 mg/ml Streptomycin (Invitrogen) and
500 mg/ml L-Glutamine (Invitrogen).
Minitumour 3D spheroid co-culture and sprouting assay
The 3-dimensional (3D) spheroid co-culture assays were
performed in Endothelial Cell Growth Medium-2 (EGM-2)
(Lonza, Basel, Switzerland), supplemented with 5% FCS (v/v),
Hydrocortisone, Epithelial Growth Factor (EGF), Insulin-like
Growth Factor-1 (IGF-1), ascorbic acid, GA-100, Heparin and
with or without bFGF and VEGF. A stock methocel solution was
prepared by dissolving 6 g of methylcellulose in 500 ml of EGM-2
medium. Cells were previously incubated in a 2 mM solution of
CellTrackerTM green CMFDA or CellTrackerTM orange CMRA
(Molecular probes, Invitrogen, UK). 750 HUVECs, 375 NHDFs
and 750 MDA-MB-231 cells were added to each well of a 96 U-
well suspension plate (Greiner BioOne, UK) in a 150 mL of EGM-
2 with 20% methocel (v/v). The cells were allowed to form
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spheroids overnight at 37uC. After spheroid formation a solution
of 1.5 mg/ml of rat tail collagen type-I (BD Biosciences, UK) was
prepared in the appropriate amount of EGM-2 medium and pH
neutralized by drop wise addition of 1 M NaOH. An initial layer
was deposited in the centre of the wells of a 12 well plate as a
droplet and allowed to set at 37uC. The spheroids were
resuspended in an equivalent solution of collagen type-I and
deposited over the first layer, and incubated at 37uC for 1.5 h-2 h
to set. After allowing the collagen gels to set, 1.5 ml of EGM-2
medium including angiogenesis inhibitors or stimulants were
added to the wells and the spheroids were allowed to form
sprouts for 2 days before fixation with 4% PFA (w/v) in HBSS
with Ca2+ and Mg2+ (Invitrogen). Function blocking antibodies
were added within the collagen matrix. For longer term
experiments spheroids were incubated for 7 days with medium
changes every 2 days before fixation with 4% PFA (w/v) in HBSS
with Ca2+ and Mg2+.
Immunocytochemistry of spheroid co-cultures
After fixing the co-cultures, the PFA was quenched with
100 mM Glycine, pH 7.4 after which the spheroids were blocked
for 1 h with 1% BSA (w/v) in PBS at room temperature (RT).
Primary antibodies were added at the appropriate dilutions in 1%
BSA in PBS and incubated at RT overnight. The spheroids were
subsequently washed for at least 8 h in 1% BSA (w/v) in PBS with
0.1% Tween (v/v), with hourly changes of the washing solution,
followed by incubation with the appropriate donkey secondary
antibody (Jackson ImmunoResearch, Stratech, UK) overnight at
RT. Finally the co-cultures were washed again with 1% BSA (w/v)
in PBS with 1% Tween (v/v) and stored in PBS at 4uC for before
imaging.
Confocal microscopy and image analysis
Spheroid sprouting was imaged with a Nikon C1Si confocal
inverted microscope (Nikon UK limited, UK), using 106
magnification. 10 spheroids from 2 different wells were imaged
per condition. Green channel confocal images corresponding to
the pre-dyed endothelial cell sprout formation were subsequently
quantified using the Metamorph (Molecular Devices, Berkshire,
UK) image analysis software. In short, a proprietary Metamorph
plug-in for Neurite Outgrowth analysis was used, which masks the
spheroid outgrowth area, separating spheroid body from sprouts.
This method provided automated measurements of Sprout Length
and Number of Sprouts for each spheroid. The quantification
method was optimized and validated, showing reproducibility
between experiments (Figure S1). For Multiphoton microscopy,
spheroids were imaged on a Leica confocal TCS SP5 microscope
using a Titanium Sapphire laser (100 fs pulses at 80 MHz,
Chameleon model from Coherent). Samples were excited with
880 nm pulses. An oil objective lens was used for excitation and
detection at the appropriate wavelengths (206 magnification
NA=0.7). Z-stack images were obtained from individual spher-
oids, and maximum projections were created with the LAS AF
Leica imaging software (Leica Microsystems GmbH, Germany).
Further 3D image treatment and analysis was performed using
VolocityH software (Improvision, Perkin-Elmer, USA).
Electron Microscopy
Minitumour spheroids cultured for 40 h or 7 days were washed
in 0.9% saline solution and fixed in 2.5% (w/v) glutaraldehyde
with one volume H2O2 at 4uC for 8 h, followed by 6 washes in
0.9% saline solution. They were treated with 1% (w/v)osmium
ferricyanide for 1 h, rinsed 4 times in DIW and bulk stained in 2%
(w/v) uranyle acetate in 0.05 M maleate buffer at pH 5.5 for 1 h.
They were rinsed 4 times in DIW and dehydrated in an ascending
series of ethanol solutions from 70% to 100% (v/v). They were
rinsed twice in dry acetonitrile and incubated in 50:50 acetonitrile
and araldite epoxy resin overnight. This mixture was replaced with
25:75 acetonitrile and araldite for 6 h followed by 4 changes in
pure araldide over 48 h. The resin castings were cured at 65uC for
48 h. One micrometre sections were cut with a histodiamond knife
(Diatome, Switzerland) on a Leica Ultracut UCT ultramicrotome.
They were stained with methylene blue and identified areas were
cut at 60 nm with a 45u wedge angle diamond knife (Diatome,
Switzerland), mounted on 200 mesh copper grids and stained with
uranyle acetate and lead citrate. They were viewed on a FEI
Tecnai G2 TEM operated at 120 kV. Images were captured with
an AMT XR60B digital camera running Deben software.
Lentiviral transduction of shRNA
Lentivirus expressing shRNAs from the U6 promoter in the
pLKO.1-puro vector containing a puromycin resistance marker
were purchased from the Sigma MissionH TRC shRNA library
and used to infect subconfluent cells in 6 well plates. Antibiotic free
medium was added to cells containing lentivirus particles at an
MOI of 2 for 4 h and replaced with fresh medium overnight.
shRNA expressing cells were subsequently selected using the
appropriate puromycin concentrations (HUVEC 0.3 mg/ml,
NHDF 1.2 mg/ml, MDA-MB-231 0.6 mg/ml). Puromycin was
removed from the cells 48 h before each experiment. QRT-PCR
analysis confirmed that knock-down is not only specific but also
did not elicit an interferon dependent non-targeted effect (data not
shown), as no significant differences were detected in expression
values of other MT-MMPs or interferon-response genes OAS1
and Mx1.
Luciferase-based measurement of tumour cell
proliferation
Minitumour spheroids were prepared using the previously
described protocol, using MDA-MB-231-luc2 cells, a MDA-MB-
231 cell line expressing the firefly luciferase (luc2) from the
ubiquitin C promoter (Caliper Life Sciences, USA). At the end of
spheroid incubation, medium was replaced with 500 mL of fresh
medium containing 1% of a 30 mg/ml luciferin stock solution
prepared from D-Luciferin potassium salt (Caliper Life Sciences).
Spheroid luminescence was imaged using the IVISH 200 imaging
system (Caliper Life Sciences). A 96 well plate containing serial
concentration dilutions of MDA-MB-231-luc2 cells in triplicates
was also imaged as a control for signal stability and linearity with
cell number. The luminescence signal was analysed as photons/
second using the Living ImageH 3.2 software from Caliper Life
Sciences.
Western blotting
Protein extracts were obtained from cell monolayers using an
SDS lysis buffer containing 50 mM Tris-HCl, pH 8.1, 10 mM
EDTA, 1% SDS (w/v), and CompleteTM EDTA-free proteinase
inhibitor cocktail (Roche Diagnostics GmbH, Switzerland).
Extracts were homogenized by sonication and cleared by
centrifugation for 15 min at 14800 RPM. Total protein concen-
tration was determined using a Bicinchoninic Acid (BCA) protein
assay kit (Pierce, Thermo Fisher Scientific) according to the
manufacturer’s instructions. Equal amounts of protein were
incubated at 100uC for 5 min in a loading buffer containing
100 mM Dithiothreitol (DTT) (Melford Laboratories, UK) and
separated by 10% SDS-PAGE using standard protocols before
transferring to a nitrocellulose membrane using a transblot semi-
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dry transfer system (BioRad, UK). Membranes were blocked in
5% (w/v) fat free milk powder (Marvel, UK) in PBS before
incubation with the primary antibody. Membranes were subse-
quently washed in PBS-Tween and incubated with the secon-
dary antibody. After further washing in PBS-Tween the
immunreactions were developed using the Amersham ECLTM
(Enhanced Chemi-luminescence) Western Blotting Detection
Reagents (GE Healthcare, UK). Band intensity was quantified
using the ImageJ software and normalized against a loading
control.
Statistical analysis
All graphs shown of spheroid outgrowth quantification
represent the averaged parameters with the Standard Error of
the Mean (SEM) as error bars. One-way ANOVA analysis with
Student Newman-Keuls post-test was performed to calculate
statistical significance, using the GraphPad Prim version 5.0 b
(GraphPad software Inc, San Diego, CA, USA). P-values are
specified in each experiment.
Results
The Minitumour spheroid model
Previously published in vitro models developed for the study of
angiogenesis regulated by cancer cells typically rely on the addition
of cancer cell conditioned medium, or separation of cancer cells
from endothelial cells by a matrix or membrane [31]. Accordingly,
reports have shown direct cell-cell contact between tumour cells
(including MDA-MB-231) and endothelial cells leads to an
increase in endothelial cell apoptosis [13]. Evidence from our
laboratory supports these observations, as the direct addition of
tumour cells to a vasculogenesis model described by Bishop et al
[18] decreased capillary formation (data not shown). We have also
observed that Human Umbilical Vein Endothelial Cells (HU-
VECs) do not form continuous sprouts solely in direct contact with
the tumour cells (data not shown).
To overcome these technical difficulties, we have co-cultured
endothelial cells, Normal Human Dermal Fibroblasts (NHDF) and
tumour cells in a spheroid before implantation in a collagen-I gel,
an adaptation of the system described by Korff et al [29]. By pre-
labelling the endothelial cells using a green cell tracker dye, it is
possible to visualise and quantify the formation of endothelial pre-
capillary sprouts from the model. The HUVECs initially mix with
the other cell types in a multicellular spheroid (Figure 1A), which
can then be implanted in a type-I collagen gel. After 40 h, confocal
imaging of green-labelled HUVECs shows the formation of pre-
capillary sprout-like structures (Figure 1B). This is, to our
knowledge, the first model to include all three components in an
in vitro system, allowing for the study of complex interactions
underlying the early steps of tumour angiogenesis. We have named
this system the Minitumour spheroid model.
By comparing the Minitumour spheroids with simpler spheroid
types, we observe that HUVECs alone form irregular projections
into the collagen matrix, with high levels of scattering cells.
However, in the presence of fibroblasts, HUVECs form contin-
uous sprouts that can be analysed and quantified in terms of their
length and number (Figure 1C and S1). Mesenchymal mural cells,
such as pericytes or fibroblasts have been extensively shown to
contribute to the development of more robust and continuous
endothelial sprouts in other in vitro systems [17,22,32]. Particularly,
the ability of fibroblasts to act as mural cells in vitro and drive the
formation of endothelial cell networks has been described before
[23,33]. Confocal imaging of Minitumour spheroids containing
both pre-dyed fibroblasts and endothelial cells showed that the
fibroblasts develop a mural cell-like phenotype in this model,
migrating in spindles adjacent to and around the endothelial cell
sprouts (Figure 1E).
The endothelial nature of the observed sprouts was confirmed
by staining for endothelial markers CD31 and CD34 (Figure S2),
showing a distribution comparable to that of the green tracker dye
used to label the HUVECs. Endothelial cell sprouts showed,
however, no staining for Lymphatic marker LYVE-1 (Figure S2),
which had been previously shown to be expressed in HUVECs
cultured in 3D but repressed in the presence of perivascular cells
[34]. This confirmed the blood endothelial phenotype of these
cells, as well as the perivascular/mural nature of the fibroblasts in
our system.
The MDA-MB-231 breast cancer cells in the model were shown
to augment endothelial cell sprouting both in the presence and
absence of exogenous angiogenic growth factors VEGF and bFGF
(Figure 1B). This confirmed the Minitumour model as a reliable
framework with which to observe the effects of tumour cells on
endothelial outgrowth and sprout formation in vitro. The MDA-
MB-231 cancer cells could also be imaged after pre-dyeing with
the CMFDA Green Cell Tracker Dye and were shown to migrate
uniformly around the spheroid within the collagen-I gel
(Figure 1D).
Minitumour spheroids and extracellular matrix structure
To investigate the interaction between the Minitumour
spheroids and their surrounding ExtraCellular Matrix (ECM),
spheroids were imaged using Multiphoton Microscopy. This was
used in order to detect the Second Harmonic Generation (SHG)
signal emitted by collagen-I matrix fibrils as well as the endothelial
cell sprout formation from the spheroids. On observing the
spheroids immediately after their implantation in the collagen
matrix, the SHG signal from the surrounding collagen is weak,
consisting mostly of a low level homogeneous signal around the
spheroids (Figure 2A and B). However, after incubation in the
collagen matrix for 40 hours, an increase in the SHG signal was
observed accumulating around the endothelial cell sprouts
(Figure 2C–F). Furthermore, it was possible to distinguish empty
paths in the SHG signal, corresponding to the areas of sprout
formation, surrounded by areas of stronger intensity (Figure 2D). It
is not clear currently if these differences in intensity are due to
matrix rearrangements (matrix displacement, degradation, fibril
formation), or due to production of new ECM (e.g. collagen-I
production and processing by fibroblasts). Nevertheless the
possibility of studying the interaction between endothelial sprout-
formation and its surrounding matrix opens interesting new
avenues of investigation, as recent work shows that the angiogenic
process can be regulated by extracellular mechanical cues [35].
After 7 days of culture, the spheroids were observed to form more
complex endothelial cell networks, which branch and interconnect
within a denser layer of fibroblasts and tumour cells (Figure 2G–I).
At this point the SHG signal from the collagen matrix is almost
ablated, possibly reflecting the degradation and reorganisation of
the matrix by the different cells in the model (Figure 2I). These
more complex endothelial networks are also shown, though the
use of transmission electron microscopy (TEM), to contain fully
developed lumens (Figure S3), which are not detected after 40 h
culture (data not shown).
Optimized immunostaining techniques also allowed us to
further dissect the deposition of additional ECM components
with endothelial sprout formation. Immunostaining for compo-
nents of the vascular basement membrane, such as Collagen IV
and Laminin, showed that these localize mostly around the
developing endothelial cell sprouts at 40 h (Figures 3A and B).
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Tenascin has been shown to be largely associated with
mesenchymal regions in tissues such as normal breast, and
secreted by fibroblasts. Its secretion is increased in neoplastic
tissue, where stromal fibroblasts are thought to be its major source
[36,37]. Likewise, pan-tenascin staining of Minitumour spheroids
showed a diffuse pattern (Figure 3C), reminiscent of the pattern of
invading fibroblasts within the model (Figure 1E).
After allowing the spheroids to grow for 7 days, the pattern of
pan-laminin staining was altered, acquiring a more widespread
distribution, with the formation of a network of fibrils along the
spheroid outgrowth area (Figure 3D). Extensive laminin produc-
tion has been reported in breast carcinomas, correlating
particularly with areas of vessel formation [38]. Laminin has also
been shown to stimulate the production of capillary-like tubules
Figure 1. Characterization of the Minitumour spheroid model. A - Fluorescent (left) and phase contrast (right) images of HUVEC, EndoFib and
Minitumour spheroids before incubation in the collagen gel; endothelial cells pre-dyed with a CMFDA Green CellTracker dye are seen in each
different spheroid type. B – Representative fluorescent images of spheroids after 48 h incubation in collagen gels, in the presence of complete
medium, showing pre-dyed endothelial cells organized into pre-capillary sprouts. C – Quantification of endothelial sprout length from different
spheroids show that MDA-MB-231 cells stimulate sprout formation even in the absence of exogenous growth factors VEGF and bFGF. D – Confocal
(upper) and phase contrast (lower) images of MDA-MB231 cells pre-dyed with the green CellTracker dye in the Minitumour spheroid after 48 h
incubation in complete medium. E - A 3D reconstruction of a Minitumour spheroid where the HUVECs have been dyed with a CMRA Orange
CellTracker dye and the fibroblasts with a CMFDA Green Cell Tracker side panels show optical x and y sections of sprouts showing the deposition of
HUVECs and Fibroblasts relative to sprout formation.
doi:10.1371/journal.pone.0030753.g001
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from endothelial cells in collagen I gels [14], suggesting the
establishment of a pro-angiogenic environment within the long
term growth of Minitumour spheroids. The pattern of collagen IV
staining after 7 days, however, still localized around endothelial
cell sprouts, providing for a suitable long-term indirect endothelial
cell marker in the model (Figure 3E). The immunoreactivity signal
for tenascin was also widespread after 7 days, similar to laminin
(Figure 3F), possibly due not only to their production by
fibroblasts, but also by the MDA-MB-231 cells, which has also
been previously documented [39].
Angiogenic signalling pathway characterization of
Minitumour spheroids
To further establish the model as a suitable tool for the study of
angiogenesis in a tumour microenvironment we characterized it in
terms of previously established signalling pathways that govern
Figure 2. Multiphoton microscopy images of Minitumour spheroids after 40 h or 7 days culture. A - HUVECs dyed with a CMFDA Green
CellTracker dye were imaged within the Minitumour spheroid immediately following their embedding into the type-I collagen matrix using a
Multiphoton microscope with a 206 objective. B – Immediately after collagen embedding, the collagen-I gel emits a weak homogenous Second
Harmonic Generation (SHG) signal. C – Multiphoton imaging from of spheroids after 40 h incubation in the collagen-I gel shows the formation of
green endothelial sprouts into the collagen matrix. D - The SHG signal from the collagen reveals an increase in matrix intensity around the endothelial
sprouts. E – Merged image between CMFDA Green CellTracker dye and SHG signals after 40 h incubation. F – A higher amplification (406) image of
an endothelial cell sprout from a Minitumour spheroid after 40 h shows the alignment of collagen fibrils along the endothelial cell sprout (white
arrows). G – Phase contrast images after 7 days incubation in the collagen-I gel showing a homogenous layer of cells. H – Multiphoton imaging after 7
days incubation shows the formation of a network of pre-dyed endothelial cells within the layer of cells. I – SHG signal from the collagen matrix after
7 days spheroid incubation. Scale bars represent 50 mm in F and 100 mm in all others.
doi:10.1371/journal.pone.0030753.g002
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pre-capillary sprout formation. For this purpose two different
approaches were used, the use of function blocking antibodies and
low molecular weight inhibitors. The use of function blocking
antibodies in our model is of interest as recent years have seen a
rise in the use of antibodies as anti-angiogenic therapeutic agents,
with the notable case of VEGF antibody Bevacizumab [40].
Antibodies to the growth factors VEGF-A and PDGF-B were
tested, due to their recognized roles in tumour angiogenesis and
stromal activation [11,41,42]. The inclusion of control immuno-
globulins within the collagen matrix did not disrupt normal sprout
formation (data not shown). Both VEGF-A and PDGF-B blocking
antibodies significantly inhibited sprouting (Figure 4A), confirming
the important role of these two growth factors in tumour
angiogenesis using the Minitumour model. This observation again
confirms that our model can reliably reproduce results seen in
other in vitro and in vivo systems.
To further explore the results seen with the functional
antibodies, low molecular weight receptor tyrosine kinase
inhibitors were used to abrogate VEGFR and PDGFR functions.
SU4312, an inhibitor of VEGFR signalling that also has a lower
affinity for PDGFR [43], almost completely ablated sprout
formation in spheroids in the presence and absence of cancer
cells (Figure 4C). This is in accordance with the results obtained
with the function-blocking antibody for VEGF. AG1296, an
inhibitor of PDGFR [44], had an interesting effect on the
spheroids. In spheroids without cancer cells (EndoFib spheroids),
contrary to an expected reduction in sprout formation, inhibition
of PDGFR appeared to increase sprout formation (Figure 4C).
Closer examination however, showed this was due to scattering of
endothelial cells rather than the formation of continuous sprouts,
which consequently led to inconsistent quantification (Figure 4E).
This scattering of endothelial cells was remarkably similar to that
seen in spheroids constituted of HUVECs alone (Figure 1B).
Considering PDGF is a well-documented stromal activator [4,19],
we speculate that this could be due to a decrease in the mural cell-
like phenotype of the fibroblasts, leading to a chaotic invasion of
endothelial cells. In the Minitumour model, AG1296 caused a
decrease in the number of endothelial sprouts, reducing them to
levels similar to those seen in the control EndoFib co-cultures (data
not shown), but it does not have a significant effect on sprout
length (Figure 4C and E), contrary to the data shown with function
blocking antibody (Figure 4A). The differences in the magnitude of
the effect might be due to intrinsic differences between the use of
immunoglobulins and small molecule inhibitors, which may
penetrate better into the spheroids, show differential selectivity
towards PDGF isoforms, or lack of selectivity towards PDGFR.
PPP is a potent inhibitor of IGF-1R [45], another growth factor
receptor that has also been implicated in tumour angiogenesis in
colorectal cancer and multiple myeloma [46]. PPP significantly
inhibited capillary sprout formation in the presence and absence of
MDA-MB-231 cells (Figure 4C).
Previous reports have shown that co-culturing MCF7 cells with
macrophages markedly increased their efficiency in inducing
endothelial cell tubule formation in vitro [47]. This effect was
dependant on the macrophage release of inflammatory cytokines
including IL-6 and IL-8. Estrogen-Receptor negative breast
cancer cell lines, which include MDA-MB-231, have also been
shown to overexpress IL-8, which is associated with a higher
invasiveness potential [48]. We hypothesised that the increase in
HUVEC sprouting in the Minitumour spheroids, compared to
spheroids without cancer cells, might be due to the secretion of
inflammatory cytokines by the MDA-MB-231 breast cancer cells.
To investigate this hypothesis we used function-blocking antibod-
ies to IL-6 and IL-8 in the Minitumour spheroids and compared
their outgrowth with EndoFib spheroids. The function blocking
antibodies against IL-6 and IL-8 significantly impaired endothelial
cell sprouting from Minitumour spheroids. While the effect was
not as marked as that seen previously with the anti-VEGF
antibody, sprouting from the Minitumour spheroids were reduced
to levels similar to those of EndoFib spheroids (Figure 4B). This
Figure 3. Immunostaining of Minitumour spheroids show deposition of extracellular matrix components. A – Minitumour spheroids
incubated in collagen-I were immunostained with an anti-pan-laminin antibody and imaged by confocal microscopy showing the deposition of
laminin around the endothelial sprouts after 40 h and D – a more widespread distribution after 7 days. B – Confocal microscopy of Minitumour
spheroids immunostained with an anti-collagen IV antibody after 48 h shows a similar pattern, E – but after 7 days collagen-IV still localized around
the endothelial cell sprouts. C – Confocal microscopy of Minitumour spheroids immunostained with an anti-Tenascin antibody show widespread
distribution after 40 h, and F – after 7 days. All images were obtained using a 106objective. Scale bars represent 100 mm.
doi:10.1371/journal.pone.0030753.g003
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Figure 4. Minitumour spheroids growth factor dependency. A – Direct incubation of function blocking antibodies for VEGF or PDGF within
the collagen-I gel decreases endothelial cell sprouting from the Minitumour spheroids. B – Minitumour spheroids incubated with function blocking
antibodies to IL6 and IL8 show similar levels of sprout formation to EndoFib spheroids. C - Minitumour and EndoFib spheroids show a differential
response to inhibition of growth factor signaling using small molecule growth factor receptor inhibitors. D – Increase in endothelial cell sprouting in
both Minitumour and EndoFib spheroids after 40 h incubation with the gamma-secretase inhibitor DAPT. E – Representative images from
Minitumour and EndoFib spheroids incubated in collagen-I for 40 h with the addition of different growth factor receptor inhibitors.
doi:10.1371/journal.pone.0030753.g004
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suggests the MDA-MB-231 contribution to increased endothelial
sprouting in the Minitumour spheroids is dependent on the
inflammatory cytokines IL-6 and IL-8.
The presenilin family of aspartyl proteinases plays a significant
role in cellular signalling by processing transmembrane receptors
[49]. This includes the processing of the Notch-Delta, Notch-
Jagged and Eph-Ephrin receptor systems that have been shown to
be important in the regulation of angiogenesis. The Notch-Delta
system has largely been described in the initial processes of
endothelial tip-cell formation, namely through Delta-like ligand 4
(Dll4) signalling [11,50]. This supports results seen with the use of
the presenilin inhibitor DAPT in our spheroid systems, which led
to a significant increase in endothelial cell sprouting Minitumour
spheroids as well as EndoFib spheroids (Figure 4D).
Minitumour spheroid response to anti-angiogenic
inhibitors
Further characterization of the model was carried out using
known anti-angiogenic agents, which have already been used in
clinical trials with mixed results (Figure 5). This had the purpose of
enabling us to understand if the model’s drug response is closer to
the pre-clinical trial results in rodents and simpler in vitro systems,
or the drug effects seen in human clinical trials.
Metalloproteinase activity is extremely important to endothelial
cell migration and tube formation [51]. Galardin (GM6001), a
broad-spectrum inhibitor of metalloproteinases [52], had a very
significant effect on spheroid sprouting, both in the Minitumour
model and spheroids with no cancer cells (Figure 5A and B).
Thalidomide was first used clinically to relieve symptoms of
morning sickness when significant developmental side effects were
observed in foetuses, causing defects in limb development caused
in part by poor development of the limb bud. This was not
detected in rodents [53]. More recently Thalidomide was shown to
be an inhibitor of angiogenesis [53]. Although it was effective in
pre-clinical and in vitro models, it failed to show a significant effect
in the treatment of some solid tumours including metastatic
colorectal, melanoma and breast cancers [54]. Thalidomide
inhibited capillary sprout formation in EndoFib spheroids, but
not in Minitumour spheroids containing MDA-MB-231 breast
cancer cells (Figure 5A and B), which agrees with previously
existing clinical data.
Endostatin is a proteolytic fragment of collagen-XVIII that has
been shown to inhibit angiogenesis through binding to integrin
a5b1 [55]. Endostatin was found to be a very effective inhibitor in
simple in vitro models and murine in vivo models but failed to show
such significant effect in human trials [56]. Endostatin inhibited
capillary sprout formation in the EndoFib spheroids, but was no
longer an inhibitor in Minitumour spheroids (Figure 5A and B).
The role of MT1-MMP in the Minitumour spheroid model
Being an in vitro model comprising different human cells lines –
primary and tumourigenic – the Minitumour spheroid model can
be used for more detailed mechanistic studies. This can be done
through independent manipulation of the different components of
the spheroids using common molecular techniques. To illustrate
this aspect of the model, the role of the metalloproteinase MT1-
MMP (Membrane-Type 1 Matrix MetalloProteinase) was ad-
dressed in the different cell types in terms of its ability to regulate
sprout formation. MT1-MMP (or MMP14) is widely expressed by
multiple cell types within the tumour microenvironment, including
endothelial cells, fibroblasts and in some instances tumour cells
[51]. MT1-MMP has also long been recognized as a major
regulator of angiogenesis [57]. It is involved in endothelial cell
migration and sprouting, and it has also been shown to up-regulate
VEGF expression, and therefore tumour angiogenesis, through
increased transcriptional activation [58]. However, the relative
contribution of this proteinase to the angiogenic process from
different cells in a tumour has yet to be clarified. In order to
address this using our model, cells stably transduced using
lentiviral delivery of short hairpin RNA (shRNA) targeting
MT1-MMP were prepared for each individual cell type. Two
different shRNAs targeting MT1-MMP were used and their
efficacy confirmed by western blot analysis (Figure 6C and F) and
qRT-PCR (data not shown), in comparison to a non-targeting
control shRNA (shCont) and the puromycin resistance expression
cassette alone (pLKO.1). All three different cell types were
independently transduced in order to determine the importance
of MT1-MMP in each of the spheroid components separately in
capillary sprout formation. In HUVECs (Figure 6A–C), the
expression of the shRNA targeting MT1-MMP resulted in a knock
down of around 50% of the protein, leading to impaired
endothelial cell sprouting. This is in accordance with previously
Figure 5. Minitumour spheroids have a different drug response than spheroids consisiting of only HUVEC and fibroblasts. A –
Incubation of EndoFib spheroids with different anti-angiogenic agents for 40 h shows inhibition of sprouting with Thalidomide, Endostatin and
Galardin. B – Incubation of Minitumour spheroids with different anti-angiogenic agents for 40 h shows a response to Galardin but a non-significant
effect of both Thalidomide and Endostatin.
doi:10.1371/journal.pone.0030753.g005
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published data recording the importance of MT1-MMP in
angiogenesis in several models, both in vitro and in vivo [57,59,60].
In fibroblasts, knock-down of MT1-MMP (about 30%) also
significantly inhibited endothelial sprout formation (Figure 6D–F).
However, knock-down of MT1-MMP in the MDA-MB-231 cells
did not have a significant effect on endothelial cell sprouting
(Figure S4). The expression of this protease, therefore, does not
seem to be necessary in the cancer cells to activate tumour
angiogenesis. However, the presence of this proteinase in
fibroblasts seems to be essential for not only their invasion, but
also that of the HUVECs, suggesting a role for the fibroblasts in
mediating endothelial cell sprout formation. The observation that
a mesenchymal derived proteinase is important for sprouting
angiogenesis is a novel one, and reveals the potential of the
Minitumour model to identify new targets and mechanisms in
tumour angiogenesis.
Having identified MT1-MMP as an important target in
stromal-mediated tumour angiogenesis, it was subsequently our
purpose to investigate if this effect could have repercussions on
cancer cell proliferation. To measure changes in cancer cell
Figure 6. MT1-MMP gene silencing in both HUVECs and fibroblasts decreases endothelial sprout formation. Cells were infected with
lentiviral particles expressing 2 different shRNAs against MT1-MMP, selected with puromycin and used to make spheroids. A – Representative images
of pre-dyed endothelial cell sprouting from Minitumour spheroids made with HUVECs transduced with the different lentiviral derived shRNAs and
controls. B – Quantification of endothelial cell sprouting showing a decrease in sprout formation with HUVECs expressing MT1-MMP shRNAs. C -
Western Blots confirming MT1-MMP knock down levels of about 50% in HUVECs, adjusted relative intensity was determined through the ImageJ
software follwed by normalization against the loading and mock controls. D – Representative images of pre-dyed endothelial cell sprouting from
Minitumour spheroids made with Fibroblasts transduced with different lentiviral derived shRNAs and controls. E – Quantification of endothelial cell
sprouting showing a decrease in sprout formation with from Minitumour spheroids with Fibroblasts expressing MT1-MMP shRNAs. F - Western blots
confirming MT1-MMP knock down levels of about 30% in the fibroblasts, adjusted relative intensity was determined through the ImageJ software
followed by normalization against the loading and mock controls.
doi:10.1371/journal.pone.0030753.g006
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number spheroids were made with MDA-MB-231-luc2 cells,
expressing luciferase from the Ubiquitin C promoter, allowing the
measurement of changes in cell number using bioluminescence
(Figure 7A and B). A sequential dilution of cancer cells was used to
establish the linear relationship between cell number and
bioluminescence signal (Figure 7A). Nocodazole was used as a
positive inhibition control and as expected decreased biolumines-
cence significantly (Figure 7C). It should be noted that, due to the
presence of cancer cells in the spheroid core, the maximum level of
bioluminescence signal reduction detectable is 50%, as seen in the
Nocodazole control (Figure 7C). No significant effect on
bioluminescence was detected after co-culturing MB231luc21H4
cells in a Minitumour spheroid with MT1-MMP depleted
fibroblasts (Figure 7D). This was confirmed by the addition of
the broad-spectrum metalloproteinase inhibitor Galardin to the
Minitumour spheroids, which also resulted in no significant
change in luminescence signal (Figure 7C).
Discussion
The use of 3D in vitro models for the study of tumour
progression is becoming established as a bona fide way to mimic
its cellular context, consequently increasing the physiological
significance of cell-based assays [24,26,27,61]. The use of
multicellular spheroids in particular has become an established
way to mimic cellular interactions in the tumour microenviron-
ment in a 3D setting when embedded in a biological scaffold
[27,62,63]. One historical limitation of this approach has been the
restriction in cell types included in the spheroid. The published
literature mainly contains examples of homotypic cancer cell
spheroids, or cancer cells in co-culture with one other type of cell,
mostly fibroblasts. This will inevitably mean several processes
associated with tumour progression will not be represented in these
models, including angiogenesis. Attempts at using multicellular
models for tumour angiogenesis studies have included cancer cell
spheroid incubation with endothelial monolayers, often resulting
in damage to the endothelial cells [64,65], or the measurement of
angiogenic factors from spheroid conditioned medium and their
use in angiogenic studies [61]. Alternatively 3D models of
angiogenesis tend to focus on the process itself, including only
endothelial cells or co-cultures with mesenchymal mural cells, and
do not include direct contact with a tumour component. In this
study, we have developed an in vitro model where stromal-driven
angiogenesis can be investigated under the direct influence of the
tumour microenvironment.
To our knowledge, the Minitumour model represents the first
time endothelial cells, fibroblasts and cancer cells are cultured in
direct cell-cell contact to activate endothelial tubule formation.
After 48 h culture, the fibroblasts are seen to behave as mural cells,
as described in the literature [17,22,23,32,33]. The MDA-MB-231
breast cancer cells are shown to induce pre-capillary sprout
formation, with or without the addition of exogenous angiogenic
growth factors such as VEGF-A and bFGF. These pre-capillary
sprouts correspond to early stages of sprouting angiogenesis,
Figure 7. Bioluminescence imaging of Minitumour spheroids reveals no difference in cancer cell proliferation with MMP inhibition.
A – Quantification of bioluminescence levels from MB231luc21H4 cell dilutions showing a linear relation between cell number and luciferase signal. B
– Representative images showing the bioluminescence signals from sequential concentration dilutions of MB231luc21H4 cells. C – Quantification of
total luminescence signal of Minitumour spheroids including MDA-MB-231-luc2 after 40 h incubation in collagen-I with galardin, a vector control and
Nocodazole as a positive control for proliferation inhibition (p-value,0.05). D – Quantification of bioluminescence signal from Minitumour spheroids
made with MB231luc21H4 and fibroblasts expressing lentiviral derived shRNAs for MT1-MMP and non-targeting controls.
doi:10.1371/journal.pone.0030753.g007
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without observed widespread lumen formation. However, spher-
oid culture for longer periods of time leads to the development of
networks of capillary structures with lumen formation, as
confirmed through the use of electron microscopy.
Incubation in type-I collagen provides a controllable 3D milieu
for spheroid incubation. The spheroid components are also shown
to produce other matrix components they require for their
invasion and sprout formation. Culturing for longer periods of
time results in the formation of a more complex capillary-like
network structure by the endothelial cells, with extensive matrix
remodelling, within a homogenous scaffold of cancer cells and
fibroblasts.
3D in vitro culture systems have been shown to reflect the in vivo
response to therapeutic agents more accurately than conventional
cell culture systems [27,61]. We have demonstrated that both
functional blocking antibodies and small molecule inhibitors can
be used in our model. This allows for detailed studies into the role
of different proteins and signalling pathways in endothelial sprout
formation in a 3D environment. It also suggests its suitability as a
platform for testing potential therapeutic agents. Minitumour
spheroids’ response to growth factor inhibitors and anti-angiogenic
compounds correlates with the existing literature, showing
dependence on a number of signalling pathways known to be
important for tumour angiogenesis in vivo. These results can be
obtained in a short time frame with high reproducibility, and
indicate the Minitumour spheroid is a relevant model of the early
stages of tumour angiogenesis. This model could therefore prove
useful not only for studies into the mechanism of sprout formation,
but also for preliminary studies of angiogenic inhibitors with
therapeutic potential. In future, Minitumour spheroids could be
developed into a high throughput format, maximising their
usefulness as a drug-screening tool. This could be achieved with
the use of liquid handling technology in order to keep the
spheroids in a 96 well format during collagen incubation. The use
of an automated imaging system could then enable the use of this
model for high content screening of anti-angiogenic agents. This
would be of particular interest since the need for physiologically
relevant screening assays that take the third dimension into
account has been identified as one of the current challenges in cell
biology [27].
Of particular interest is the model’s response to Endostatin and
Thalidomide. The addition of these compounds to Minitumour
spheroids resulted in decreased inhibition of capillary sprout
formation, suggesting the model could be used to investigate
mechanisms of tumour resistance to these anti-angiogenic
inhibitors. Data obtained using the gamma secretase inhibitor
DAPT is also of relevance. It could open new avenues of
investigation in the importance of heterotypical notch signalling in
tumour angiogenesis, as this pathway has also been shown to be
important in the communication between endothelial and mural
cells, for example through activation of Notch3 in mural cells by
endothelial cell-expressed Jagged-3 [33]. Using the Minitumour
model, this mechanism could be studied in further depth, as mural
and endothelial cells can be manipulated individually, leading to a
better understanding of the relative importance of the notch-delta/
jagged components involved the different compartments in the
regulation of sprout formation.
A strong asset of this model is the fact that all separate
components can be manipulated independently using common
molecular techniques to dissect mechanisms regulating the
sprouting process. Using this approach it was possible to identify
new roles for fibroblasts in mediating sprouting angiogenesis,
particularly through the expression of the metalloproteinase MT1-
MMP. Its expression is essential in HUVECs to mediate their
migration process and angiogenesis in a number of systems. MT1-
MMP has also been shown to be required for pericyte recruitment
in vivo [57]. In our model, we demonstrate that the presence of this
proteinase in fibroblasts seems to be essential for not only their
invasion but also that of the HUVECs, suggesting a role for mural
cells in mediating endothelial cell sprout formation. The novel
observation that stromal derived proteinases are important for
sprouting angiogenesis reveals the potential of the Minitumour
model to identify new targets and mechanisms in tumour
angiogenesis. These observations open new avenues of investiga-
tion that can be explored in the future.
While the Minitumour spheroid was developed primarily as a
model of tumour angiogenesis, future work could be done in order
to extend its scope towards the study of cancer cells. In this study
we used luciferase-based technology for this purpose to study
cancer cell proliferation and we were able to show MT1-MMP in
the fibroblasts does not regulate cancer cell number in our system.
The use of immunostaining techniques as well as the pre-dyeing of
cancer cells could also be extended in the future in order to use this
model to study the effects of the stroma in cancer cell invasion and
proliferation. Our model can therefore provide for an advanta-
geous tool where the behaviour of all included cells can be studied
in a complex system. Cells constitutively expressing different
fluorophores could potentially be used for a dynamic look into the
invasive behaviour of fibroblasts and/or cancer cells under the
influence of a heterogeneous environment. Allied to the potential
high-throughput developments discussed, this could lead to a
model where the invasive behaviour of all three different cell lines
could be studied in an integrative systemic way, within the same
complex environment.
In summary, we present the first example of an in vitro model
where the endothelial cells are cultured directly with cancer cells as
well as a stromal component in a 3D setting. We demonstrate the
model is readily analysed, manipulated and responds to inhibitors
of angiogenesis and tumour growth in a manner that mimics in vivo
observations. Initial studies using the Minitumour model have
allowed us to unravel new roles for mesenchymal MT1-MMP in
regulating endothelial sprout formation. Being highly reproducible
and easily manipulated, we believe it is a powerful new tool for the
study of tumour angiogenesis in vitro, opening the way for the
development of innovative insights into this process.
Supporting Information
Figure S1 Validation of Minitumour spheroid out-
growth quantification using a broad-spectrum metallo-
proteinase inhibitor. A – Quantification of total endothelial
cell sprout length from Minitumour spheroids after incubation
with galardin or a vehicle control. B – Quantification of the total
number of endothelial cell sprouts from Minitumour spheroids
after incubation with galardin or a vehicle control. C – Analysis of
number of endothelial cell sprouts counted manually from 1 mm
step z-stacks from 10 different Minitumour spheroids analysed
using the image analysis programme Volocity. D – Representative
3D reconstruction of a Minitumour z-stack using the programme
Volocity. E – Linear regression analysis of the percentage
inhibition of total spheroid sprouting by Galardin in 2D vs 3D.
F – Linear regression analysis of the percentage inhibition of total
spheroid sprouting by Galardin in 2 different experiments.
(TIF)
Figure S2 Minitumour spheroid pre-capillary sprouts
have an endothelial phenotype. A – Minitumour spheroids
containing endothelial cells pre-dyed with a CMFDA green
tracker dye and incubated in collagen-I were immunostained with
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endothelial markers CD31 and CD34 and lymphatic marker
LYVE-1. CD31 and CD34 show a staining pattern corresponding
to that of pre-dyed endothelial cells, while these show no staining
for LYVE-1. B – 3-dimensional reconstructions of spheroids,
showing pre-dyed green endothelial cells as well as red staining for
the markers indicated (CD31, CD34 and LYVE-1).
(TIFF)
Figure S3 Minitumour spheroids cultured for 7 days
show lumen formation. Minitumour spheroids cultured for 7
days were fixed with glutaraldehyde, embedded in araldite epoxy
resin, sectioned and imaged using a Tecnai G2 transmission
electron microscope. Four different representative images are
presented showing lumen formation (asterisk). Black arrow
indicates a dying cell inside a lumen, probably in the process of
its formation. f – fibroblast. Scale bar corresponds to 2 mm in A, B,
C and 500 nm in D.
(TIFF)
Figure S4 MT1-MMP gene silencing in MDA-MB-231
cells has no effect on endothelial cell sprout formation.
MDA-MB-231 breast cancer cells were infected with lentiviral
particles expressing 2 different shRNAs against MT1-MMP and a
puromycin resistance marker, selected with puromycin and used to
make spheroids. A – Representative images of pre-dyed endothe-
lial cell sprouting from Minitumour spheroids made with MDA-
MB-231 cells transduced with different lentiviral derived shRNAs
and controls. B – Quantification of endothelial cell sprouting
showing no difference in sprout formation from Minitumour
spheroids containing MDA-MB-231 cells expressing MT1-MMP
shRNAs. C - Western Blots showingMT1-MMP knock down
levels in HUVECs.
(TIF)
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